Key result
TAVR shows similar 5-year all-cause mortality or disabling stroke vs SAVR in low-risk aortic stenosis.
Why the study?
The authors aimed to compare the 5-year clinical and echocardiographic outcomes of isolated TAVR versus isolated SAVR among low-risk patients with severe aortic stenosis in the Evolut Low Risk Trial.
Does isolated TAVR reduce the composite of all-cause mortality or disabling stroke compared to isolated SAVR in low-risk patients with severe aortic stenosis?
RCT (n=1,164)
Does isolated TAVR reduce the composite of all-cause mortality or disabling stroke compared to isolated SAVR in low-risk patients with severe aortic stenosis?
In low-risk patients with severe aortic stenosis, isolated TAVR and isolated SAVR provide similar 5-year rates of mortality and disabling stroke, though TAVR is associated with higher rates of permanent pacemaker implantation.
Answers are grounded in this paper and cite their sources.
Supports either isolated TAVR or SAVR in low-risk aortic stenosis; extends trial data but leaves open questions on pacemaker impact.
BACKGROUND: We aim to compare the 5-year outcomes of patients who received isolated transcatheter aortic valve replacement (TAVR) versus those who underwent isolated surgical aortic valve replacement (SAVR) from the Evolut Low Risk Trial. METHODS: In the Evolut Low Risk trial, 1,414 low-risk patients with severe aortic stenosis underwent TAVR using a self-expanding, supra-annular CoreValve, Evolut R, or PRO bioprosthesis or SAVR. This post hoc analysis excluded 250 patients, those with concomitant procedures (e.g., percutaneous coronary intervention and coronary artery bypass grafting performed) and those who experienced crossover between treatment arms. Five-year clinical and echocardiographic outcomes are reported. RESULTS: A total of 1,164 patients underwent an isolated procedure (667 TAVR, 497 SAVR). At 5 years, the composite of all-cause mortality or disabling stroke was similar between the isolated groups (15.5% TAVR, 14.6% SAVR; P=.84). All-cause mortality (13.5% TAVR, 12.8% SAVR; P=.85) and cardiovascular mortality (6.9% TAVR, 8.3% SAVR; P=.36) were also comparable. New permanent pacemaker implantation was higher with TAVR (27.3% vs 8.9%, P<.001). The 5-year rate of aortic valve reintervention was 3.0% for TAVR and 2.2% for SAVR (P=.51). Moderate or greater paravalvular regurgitation (PVR) occurred in 0.5% of TAVR patients and none of the SAVR patients (P=.52) at 5 years. CONCLUSIONS: This post hoc analysis of the Evolut Low Risk Trial in patients undergoing isolated TAVR or SAVR demonstrates similar rates of all-cause mortality, reintervention, and ≥moderate PVR at 5 years, supporting Evolut TAVR as a suitable treatment option in carefully selected low-risk patients undergoing isolated valve replacement.
No takes yet. Share an insight, caveat, or question.
Ramlawi et al. (2026) conducted an RCT in severe aortic stenosis (n=1,164). Isolated transcatheter aortic valve replacement (TAVR) vs. Isolated surgical aortic valve replacement (SAVR) was evaluated on composite of all-cause mortality or disabling stroke (p=.84). Isolated TAVR resulted in similar 5-year rates of all-cause mortality or disabling stroke compared to isolated SAVR in low-risk patients with severe aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: